Global Alzheimer's Disease Market, By Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Magnetic Resonance Imaging, Lumbar Puncture Test, Electroencephalography, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Global Alzheimer’s Disease Market Analysis and Size
In recent years, the Alzheimer’s disease market is anticipated to grow rapidly during the forecast period. In advanced stages of the disease, all memory and mental functions may be lost. According to the World Health Organization's September 2021 report, around 55 million people worldwide suffer from dementia, with nearly 10 million cases recorded each year. According to the same source, Alzheimer's disease is the most common kind of dementia, accounting for 60-70 percent of all dementia cases. Because of the rising prevalence of Alzheimer's disease around the world, governments and non-governmental organizations are spending extensively in the development of diagnostics and therapies for the condition, which could boost market growth.
- Data Bridge Market Research analyses that the Alzheimer’s disease market was valued at USD 4.71 billion in 2021 and is expected to reach USD 8.98 billion by 2029, registering a CAGR of 8.40% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Alzheimer’s Disease Market Definition
Alzheimer's disease is a neurological condition in which the brain shrinks (atrophy) and brain cells die. Alzheimer's disease is the most prevalent cause of dementia, which is characterised by a progressive loss of cognitive, behavioral, and social abilities that impairs a person's capacity to operate independently. Medications may improve or reduce the course of symptoms temporarily. These therapies can help patients with Alzheimer's disease keep function and independence for a short period of time. People with Alzheimer's disease and their caregivers can benefit from a variety of programmes and services.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Magnetic Resonance Imaging, Lumbar Puncture Test, Electroencephalography, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Merz Pharma (Germany), AstraZeneca (UK), Amgen Inc. (US), AbbVie Inc. (US), Biogen (US), Siemens Healthcare GmbH (Germany)
|
|
Market Opportunities
|
|
Alzheimer’s Disease Market Dynamics
Drivers
-
Increasing prevalence of chronic diseases
The rising prevalence of chronic diseases such as dementia is a primary driver of the global visual impairment market's growth.
-
Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Alzheimer’s disease market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Alzheimer’s disease market. Additionally, high disposable income and increasing drug development for its cure and treatment will result in the expansion of Alzheimer’s disease market. Along with this, rising geriatric population and changing lifestyle of people will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Alzheimer’s disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Alzheimer’s disease market growth during the forecast period.
Restraints/Challenges Global Alzheimer’s Disease Market
On the other hand, the high cost associated with the treatment of Alzheimer’s disease will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Alzheimer’s disease market. Additionally, strict regulations and the dearth of cure for this illness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Alzheimer’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Alzheimer’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Alzheimer's illness affects around 5.8 million individuals in the United States aged 65 and up. 80% of them are 75 years old or older. Alzheimer's disease is considered to trigger 60 percent to 70 percent of the world's 50 million individuals with dementia.
Alzheimer’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Alzheimer’s Disease Market
Coronavirus, a global outbreak, is affecting people all over the world. Except for the pharmaceutical business, it has had a negative impact on all industries' operations. This has also had an impact on the Alzheimer's disease diagnostic industry. Following the COVID-19 incident, it is expected that the Alzheimer's disease Diagnostic Market Share will skyrocket. According to a survey published in the United Kingdom, COVID 19 has the greatest mortality rate among dementia patients. Patients with dementia's mental health has been negatively impacted by social separation, which was the order of the day during the coronavirus pandemic. The pandemic situation has created several adjustments in Alzheimer's patients' everyday routines, which has had a significant influence on their health.
Recent Development
- In June 2021, U.S. Food and Drug Administration (FDA) had approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. Aduhelm was approved through the accelerated approval procedure, which can be used for a medicine that treats a serious or life-threatening illness and offers a significant therapeutic benefit over existing treatments. With a mandatory post-approval trial to verify that the medicine produces the projected clinical benefit, accelerated approval can be based on the drug's effect on a surrogate endpoint that is fairly likely to predict a therapeutic benefit for patients.
Global Alzheimer’s Disease Market Scope
The Alzheimer’s disease market is segmented on the basis of type, therapeutics, diagnostics, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Early-onset Alzheimer's
- Late-onset Alzheimer's
- Familial Alzheimer's disease
On the basis of type, the Alzheimer’s disease market is segmented into early-onset Alzheimer's, late-onset Alzheimer's, and familial Alzheimer's disease.
Therapeutics
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Others
On the basis of therapeutics, the Alzheimer’s disease market is segmented into cholinesterase inhibitors, NMDA receptor antagonists and others.
Diagnostics
- Magnetic Resonance Imaging
- Lumbar Puncture Test
- Electroencephalography
- Others
On the basis of diagnostics, the Alzheimer’s disease market is segmented into magnetic resonance imaging, lumbar puncture test, electroencephalography and others.
Route of Administration
- Oral
- Parenteral
- Others
The route of administration segment for the Alzheimer’s disease market is segmented into oral, parenteral and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the Alzheimer’s disease market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Alzheimer’s disease market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others
Alzheimer’s Disease Market Regional Analysis/Insights
The Alzheimer’s disease market is analysed and market size insights and trends are provided by country, type, therapeutics, diagnostics, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Alzheimer’s disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Asia-Pacific dominates the Alzheimer’s disease market because of the rising healthcare expenditure and growing prevalence of Alzheimer’s disease in this region. Additionally, rising number of population will further propel the market’s growth rate in this region.
Europe and North America are expected to grow during the forecast period due to rising number of research and development activities and growing focus of major key players on novel technology in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Alzheimer’s Disease Market Share Analysis
The Alzheimer’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Alzheimer’s disease market.
Some of the major players operating in the Alzheimer’s disease market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- Bristol-Myers Squibb Company (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Merz Pharma (Germany)
- AstraZeneca (UK)
- Amgen Inc. (US)
- AbbVie Inc. (US)
- Biogen (US)
- Siemens Healthcare GmbH (Germany)
SKU-